Clinical bottom line
Allergic reactions to novel mRNA cancer vaccines represent an emerging clinical concern as these therapies gain wider adoption. Current evidence suggests that while immediate hypersensitivity reactions, including anaphylaxis, are rare, clinicians should be vigilant in identifying and managing such events promptly. Diagnostic approaches adapted from COVID-19 mRNA vaccine experience, including skin testing and graded challenge protocols, may be applicable but require validation in the oncology context. Management strategies emphasize risk stratification, premedication, and readiness for emergency intervention. Given the novelty of mRNA cancer vaccines, ongoing surveillance and research are essential to refine best practices.
What the evidence shows
mRNA-based cancer vaccines are a promising immunotherapeutic modality under active development for malignancies such as melanoma and lung cancer (Prabhakar et al., 2025; Ramos et al., 2025). These vaccines utilize lipid nanoparticle-encapsulated mRNA to induce tumor-specific immune responses (Ni et al., 2023). Although clinical trials have primarily focused on efficacy and safety, emerging reports highlight the potential for allergic reactions analogous to those observed with COVID-19 mRNA vaccines (Rubin et al., 2021).
The incidence of acute allergic reactions to COVID-19 mRNA vaccines has been estimated at approximately 2 to 5 cases per million doses, with anaphylaxis being exceedingly rare (Rubin et al., 2021; Reactions Weekly, 2021). These reactions are hypothesized to be related to excipients such as polyethylene glycol (PEG) present in the lipid nanoparticles (Bekis Bozkurt et al., 2024). Given the structural and formulation similarities, mRNA cancer vaccines may carry a comparable risk profile, although direct data remain limited.
Diagnostic evaluation for suspected allergic reactions to mRNA vaccines currently involves detailed clinical history, skin prick and intradermal testing with vaccine components, and, when appropriate, graded vaccine challenge under medical supervision (Maki et al., 2021; Bekis Bozkurt et al., 2024). These approaches have been developed primarily in the context of COVID-19 vaccination but provide a framework for assessing hypersensitivity in cancer vaccine recipients.
Management recommendations emphasize pre-vaccination risk assessment, including identification of prior PEG or vaccine component allergies, and preparedness for immediate treatment of anaphylaxis with intramuscular epinephrine (Maki et al., 2021). Premedication with antihistamines or corticosteroids may be considered on a case-by-case basis but lacks robust evidence. Close monitoring post-vaccination for at least 30 minutes is advised for high-risk individuals.
Caveats and uncertainty
The evidence base for allergic reactions to mRNA cancer vaccines is currently extrapolated largely from COVID-19 vaccine experience and early-phase cancer vaccine trials, which have not systematically reported hypersensitivity events (Ni et al., 2023; Prabhakar et al., 2025). The true incidence and mechanisms of allergic reactions specific to cancer vaccine formulations remain to be elucidated.
Differences in antigenic targets, dosing schedules, and patient populations (often immunocompromised oncology patients) may influence both the risk and presentation of allergic reactions. Furthermore, the role of PEG and other excipients in provoking hypersensitivity in this context is not fully characterized.
Diagnostic skin testing protocols validated for COVID-19 vaccines may not have the same sensitivity or specificity for cancer vaccines, necessitating prospective validation studies. Similarly, the safety and efficacy of desensitization or graded challenge protocols in this population are unproven.
Finally, the potential impact of allergic reactions on cancer vaccine efficacy and patient outcomes is unknown, warranting cautious interpretation and individualized clinical decision-making.
How this may change practice
Allergy clinicians should anticipate an increasing need to evaluate and manage allergic reactions related to mRNA cancer vaccines as these therapies enter broader clinical use. Incorporating risk assessment protocols adapted from COVID-19 vaccine experience can facilitate early identification of at-risk patients.
Development of standardized diagnostic algorithms, including skin testing with vaccine components, will be critical to differentiate true IgE-mediated allergy from non-allergic adverse events. Allergy specialists may play a key role in guiding safe vaccine administration through graded challenges or desensitization protocols when indicated.
Multidisciplinary collaboration with oncology teams is essential to balance the risks of allergic reactions against the potential benefits of cancer vaccination, particularly in patients with prior vaccine hypersensitivity or complex allergic histories.
Ongoing pharmacovigilance and research into the immunopathology of allergic reactions to mRNA cancer vaccines will inform evidence-based updates to guidelines and improve patient safety.